Abstract :
Background and Aims:
Stress-related mucosal damage (SRMD) is an important cause of acute upper2 receptor blockers (H2RB), proton pump inhibitors2RBs and PPIs,2RB in SRMD
Methods:
from July 2007 to December 2007 were recruited. Twenty-three patients who fulfilled inclusion and exclusion criteria
were randomly divided to receive either oral rebamipide or intravenous ranitidine. Endpoints were UGIB, death,
no further risk of SRMD bleeding, discharge from ICU or patient withdrawal. The measured study outcomes were
UGIB rate, HAP/VAP rate, in-hospital mortality rate and percentages of changes in serum nitric oxide (NO) level.
High-risk patients admitted to the neurosurgical ICU, Maharaj Nakorn Chiang Mai Hospital
Results:
between the two groups (sex, age, previous history of PUD/UGIB, Glasgow coma score, mean arterial pressure,
platelet count, INR, aPTT ratio, ALT, Cr, time of mechanical ventilation, NPO time, length of ICU stay or corticosteroid
use) were noted. No adverse drug reactions were detected in the study. The results of endpoints were as
follow: 6 UGIB (26.1%), 6 deaths (13%), 11 without further risk of SRMD bleeding (47.8%) and 3 withdrawals
(13%). All outcomes (UGIB rate, HAP/VAP rate, in-hospital mortality rate, percentage of changes in serum NO)
were not significantly different between the two groups.
No statistical differences in any of the baseline clinical characteristics and laboratory data
Conclusion:
in SRMD bleeding prophylaxis for high-risk neurosurgical patients were detected in this study. Rebamipide may
have effective choice in SRMD bleeding prophylaxis strategy. Larger multicentre clinical trials are needed to
confirm the observation.
No statistically significant differences between oral rebamipide and intravenous ranitidine
gastrointestinal bleeding (AUGIB) in high-risk critical patients. H
(PPIs) and sucralfate are important prophylactic drugs. Nevertheless, these agents, especially H
are associated with higher rates of hospital-acquired or ventilator-associated pneumonia (HAP or VAP) in such
setting. The aim of this study was to evaluate the efficacy of rebamipide in comparison with an H
bleeding prophylaxis for high-risk neurosurgical patients. |
file/Thai-Journal-of-gastroenterology-vol-10-no-1-4754421.pdf